Generic drug: omacetaxine mepesuccinate
Brand name: Synribo
What is Synribo (omacetaxine mepesuccinate), and how does it work?
- that is in the chronic phase or accelerated phase, and
- who have not responded to (resistant) or cannot tolerate 2 or more medicines called tyrosine kinase inhibitors.
It is not known if Synribo is safe and effective in children.
What are the side effects of Synribo?
Synribo can cause serious side effects including:
- Low blood counts. Low blood counts are common when using Synribo, including low red blood cells, white blood cells, and platelets, and can be severe. If your white blood cell count becomes very low, you are at increased risk for infection which can lead to death. Your healthcare provider will check your blood counts regularly during treatment with Synribo. Tell your healthcare provider right away if you get any of the following symptoms:
- Bleeding. Synribo causes severe low platelet counts that may increase your risk of severe bleeding. Severe low platelet counts can cause you to have bleeding in your brain that can lead to death, or severe stomach bleeding. Your healthcare provider will check your platelet counts regularly during treatment with Synribo. Tell your healthcare provider right away if you get any of the following symptoms:
The most common side effects of Synribo include:
- redness, swelling, or pain at injection site; and
You may have hair loss during treatment with Synribo. Synribo may cause fertility problems in males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.
These are not all of the side effects of Synribo.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage for Synribo?
- The recommended starting schedule for induction is 1.25 mg/m² administered subcutaneously twice daily at approximately 12 hour intervals for 14 consecutive days every 28 days, over a 28-day cycle.
- Cycles should be repeated every 28 days until patients achieve a hematologic response.
- The recommended maintenance schedule is 1.25 mg/m² administered subcutaneously twice daily at approximately 12 hour intervals for 7 consecutive days every 28 days, over a 28-day cycle.
- Treatment should continue as long as patients are clinically benefiting from therapy.
Dose Adjustments And Modifications
- Synribo treatment cycles may be delayed and/or the number of days of dosing during the cycle reduced for hematologic toxicities (e.g. neutropenia, thrombocytopenia).
- Perform complete blood counts (CBCs) weekly during induction and initial maintenance cycles.
- After initial maintenance cycles, monitor CBCs every two weeks or as clinically indicated.
- If a patient experiences Grade 4 neutropenia (absolute neutrophil count (ANC) less than 0.5 x 109/L) or Grade 3 thrombocytopenia (platelet counts less than 50 x 109/L) during a cycle, delay starting the next cycle until ANC is greater than or equal to 1.0 x 109/L and platelet count is greater than or equal to 50 x 109/L. Also, for the next cycle, reduce the number of dosing days by 2 days (e.g. to 12 or 5 days).
- Manage other clinically significant non-hematologic toxicity symptomatically. Interrupt and/or delay Synribo until toxicity is resolved.
Is Synribo safe to use while pregnant or breastfeeding?
- Based on its mechanism of action and findings from animal studies, Synribo can cause fetal harm when administered to pregnant women.
- There are no available data on Synribo use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- There are no data on the presence of omacetaxine mepesuccinate in either human or animal milk, the effects on the breastfed child, or the effects on milk production.
- Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with Synribo, and for 2 weeks after the final dose.
Multimedia: Slideshows, Images & Quizzes
Blood Cancer Types: Leukemia, Lymphomas, Myelomas, and More
Types of blood cancers include leukemia, lymphomas, multiple myelomas, and others discussed in this slideshow. Symptoms may...
Cancer: Guide to Leukemia
Learn about the common types and stages of leukemia, who gets it, symptoms, tests, treatments, and more. People with blood cancer...
What do you know about leukemia? Did you know there are different types? What are the symptoms? Take the Leukemia Quiz and test...
Related Disease Conditions
What Is the Life Expectancy of a Person With Leukemia?
Leukemia is a group of cancers of the blood affecting the white blood cells. White blood cells are the infection-fighting cells of the body. In adults, leukemia is most common in people older than 55 years, with the average age of diagnosis being 66 years. It is also one of the most common cancers in children and adults younger than 20 years. The survival rate is higher for younger people.
Leukemia is a type of cancer of the blood cells in which the growth and development of the blood cells are abnormal. Strictly speaking, leukemia should refer only to cancer of the white blood cells (the leukocytes) but in practice it can apply to malignancy of any cellular element in the blood or bone marrow, as in red cell leukemia (erythroleukemia).
How Does Leukemia Kill?
Leukemia is a cancer of the white blood cells of the bone marrow. Patients with leukemia have an over-production of a particular blood cell type in the body, the white blood cells (cells that fight infection, and provide immunity).
Survival Rate for Acute Lymphoblastic Leukemia
The prognosis depends on the type of leukemia, the extent of the disease, age of the patient, and the general condition of the patient. Some patients can go into complete remission. The average five-year survival rate of leukemia is 60-65%.
Leukemia: Signs, Symptoms, And Complications
Leukemia results when the genetic material (DNA) of a single cell in the bone marrow transforms, this is called a mutation. A mutated cell does not perform body function, but it eats away the nutrition meant for the normal cells.
Childhood Acute Lymphoblastic Leukemia (ALL)
Childhood acute lymphoblastic leukemia is the most common type of cancer in children. Symptoms and signs include fever, easy bruising, bone or joint pain, weakness, loss of appetite, and painless lumps in the neck, underarm, stomach, or groin. Treatment depends upon staging and may include chemotherapy, radiation, or stem cell transplant.
What Are the Stages of Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia is a cancer of the blood and bone marrow. With this type of cancer, the marrow creates too many abnormal lymphocytes. There are five stages of chronic lymphocytic leukemia.
Treatment & Diagnosis
- Leukemia FAQs
- Evolution of Treatment for a Rare Type of Leukemia
- Gleevec and Chronic Myeloid Leukemia
- How Familes Cope with a Leukemia Diagnosis
- Coping with a Bad Disease - Community Counts
- A Family's Leukemia Diary - Coping
- Is Multiple Myeloma the Same as Leukemia?
- Does Folic Acid Prevent Leukemia?
- Can Folic Acid Prevent Leukemia?
- Chronic Myelogenous Leukemia (CML)
Medications & Supplements
Latest Cancer News
- Breast Cancer Patients Who Can Skip Post-Op Chemo
- Evidence That Pandemic Delayed Cancer Diagnosis
- Do Immune-Based Cancer Drugs Work Better in Men?
- HPV Vaccine Is Reducing Cervical Cancers in Teens
- Old Spice, Secret Products Recalled Due to Benzene
- Want More News? Sign Up for MedicineNet Newsletters!
Daily Health News
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.